posted on 2016-01-26, 00:00authored byAne Ruiz-de-Angulo, Aintzane Zabaleta, Vanessa Gómez-Vallejo, Jordi Llop, Juan C. Mareque-Rivas
Development of vaccines to prevent
and treat emerging new pathogens
and re-emerging infections and cancer remains a major challenge. An
attractive approach is to build the vaccine upon a biocompatible NP
that simultaneously acts as accurate delivery vehicle and radiotracer
for PET/SPECT imaging for ultrasensitive and quantitative in vivo imaging of NP delivery to target tissues/organs.
Success in developing these nanovaccines will depend in part on having
a “correct” NP size and accommodating and suitably displaying
antigen and/or adjuvants (e.g., TLR agonists). Here
we develop and evaluate a NP vaccine based on iron oxide-selective
radio-gallium labeling suitable for SPECT(67Ga)/PET(68Ga) imaging and efficient delivery of antigen (OVA) and TLR
9 agonists (CpGs) using lipid-coated magnetite micelles. OVA, CpGs
and rhodamine are easily accommodated in the hybrid micelles, and
the average size of the construct can be controlled to be ca. 40 nm in diameter to target direct lymphatic delivery
of the vaccine cargo to antigen presenting cells (APCs) in the lymph
nodes (LNs). While the OVA/CpG-loaded construct showed effective delivery
to endosomal TLR 9 in APCs, SPECT imaging demonstrated migration from
the injection site to regional and nonregional LNs. In correlation
with the imaging results, a range of in vitro and in vivo studies demonstrate that by using this microdosed
nanosystem the cellular and humoral immune responses are greatly enhanced
and provide protection against tumor challenge. These results suggest
that these nanosystems have considerable potential for image-guided
development of targeted vaccines that are more effective and limit
toxicity.